Tonghua Dongbao announces NMPA acceptance of registration application for empagliflozin

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a notification of acceptance from the National Medical Products Administration (NMPA) on the registration application for empagliflozin.

Tonghua Dongbao 2021 milestones—value-driven innovation and R&D

2021 was a bumper year for Tonghua Dongbao's innovation and transformation. The Company is fast-tracking its biomedical innovation by fully focusing on the R&D of novel drugs, expanding R&D pipelines, and improving R&D efficiency. It is also extending its reach to the treatments of endocrine diseases other than diabetes. At the same time, the Company is striving to build a high-quality, innovative R&D team, which now consists of about 400 professionals with a doctorate or master's degree.

Tonghua Dongbao announces NMPA acceptance of registration application for empagliflozin DS

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a notification of acceptance from the National Medical Products Administration (NMPA) on the registration application for empagliflozin drug substance (DS).

Tonghua Dongbao 2021 estimated results: Net profit attributable to parent up 43.40% YoY

On the evening of January 24, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its financial estimated results for 2021. Specifically, the revenue is estimated to hit RMB 3.252 billion, up 12.45% YoY, the net profit attributable to owners of the parent company grew 43.40% YoY to RMB 1.334 billion, the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, rose 17.54% YoY to RMB 1.123 billion. The basic earning per share (EPS) was RMB 0.66, up 43.48% YoY.

Tonghua Dongbao: Clinical trial application for BC Combo accepted

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Tonghua Dongbao") received the notification of acceptance from the National Medical Products Administration (NMPA) on the clinical trial application for BC Combo (THDB0207 injection), a soluble insulin glargine and insulin lispro injection. The acceptance number is CXSL2101513 Guo.

Tonghua Dongbao: URAT1 inhibitor (THDBH130 Tablets) is approved for clinical trial

On December 15, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval (No. CXHL2101548 and CXHL2101549) from the Center for Drug Evaluation of the National Medical Products Administration for the clinical trial of its URAT1 inhibitor (THDBH130 Tablets).